sarepta therapeutics layoffs

News

Sarepta, black box

Sarepta Stock Soars 30%. Why Layoffs and a ‘Black-Box’ Warning Are Good News.

Sarepta Therapeutics stock soared over 30% after the pharmaceutical company said it would lay off about 500 employees. It will also add a black-box warning to its controversial gene therapy Elevidys.Shares of Sarepta were up 34% to $24.

Reuters · 1d

Sarepta to cut 500 jobs, add black-box warning on gene therapy

Sarepta Therapeutics will cut 500 jobs and add a serious warning on the label of its muscle-disorder gene therapy Elevidys, the drugmaker said on Wednesday, following the recent deaths of two patients who were on the medicine.

Investopedia on MSN · 1d

Sarepta Therapeutics Stock Soars on Beleaguered Drugmaker's Restructuring Plan

Key Takeaways Shares of drug developer Sarepta Therapeutics jumped in extended trading Wednesday after the company unveiled a major restructuring plan.The plan involves cutting 36% of its workforce and pausing several programs in its pipeline.

Sarepta Therapeutics to lay off 1-third of its workforce

The Boston Globe · 1d

Sarepta Therapeutics lays off one-third of workforce in drastic cost-cutting

The drastic cost-cutting move follows the deaths of two teenagers that forced the company to restrict usage of its gene therapy for Duchenne muscular dystrophy.

The Business Journals · 8h

Sarepta Therapeutics to lay off one-third of its workforce after gene therapy setback

Sarepta Therapeutics is facing a challenging period after the deaths of two patients who received its Columbus-invented gene therapy for Duchenne muscular dystrophy. Sarepta opens Columbus R&D center,

BioPharma Dive · 1d

Sarepta to lay off about 500 employees after Duchenne gene therapy setbacks

The company is also pausing research for several treatments it has been developing for another form of muscular dystrophy.

15h

Sarepta Therapeutics: What's Happening With SRPT Stock?

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

STAT6h

Inside an FDA drug rejection, and layoffs at Sarepta

Just how many employees is Sarepta Therapeutics laying off? And why did the FDA reject Ultragenyx's rare disease drug over ...

1don MSN

Sarepta Therapeutics rises after restructuring, pipeline focus

Sarepta Therapeutics (NASDAQ:SRPT) saw its stock rise in after-hours trading following the announcement of a strategic review ...

BioSpace11h

Sarepta Up 18% After Business Overhaul as Analysts Cautiously Optimistic

Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...

Schaeffer's Investment Research11h

Biotech Stock Soars on Restructuring Plan, Layoffs

Biopharma stock Sarepta Therapeutics Inc (NASDAQ:SRPT) is soaring today, up 20.6% at $22.17 at last glance. The biopharmaceutical company announced a strategic restructuring plan, laying off about 500 ...

Sarepta: Safety And Efficacy Flaws Undermine Gains On Restructuring News

Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...

BioSpace1d

FDA Layoffs, 200 Rejection Letters, User Fees and Priority Vouchers, Bad Week for Rare Disease

Around 3,500 FDA employees received termination emails; FDA Commissioner Marty Makary suggests lowering industry user fees ...

STAT1d

Sarepta Therapeutics lays off one-third of workforce in drastic cost-cutting move

Sarepta Therapeutics announced it has laid off more than one-third of its workforce, a drastic cost-cutting move following ...

1don MSN

JPMorgan Cuts Sarepta (SRPT) PT, Keeps Overweight Rating

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the 10 Best Small-Cap Stocks to Buy According to Billionaires. On July 10, ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results